CTMX vs. BTMD, CGC, ALMS, ZYBT, LFVN, VYGR, DSGN, FDMT, LFCR, and CCCC
Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include biote (BTMD), Canopy Growth (CGC), Alumis (ALMS), Zhengye Biotechnology (ZYBT), LifeVantage (LFVN), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.
CytomX Therapeutics vs.
biote (NASDAQ:BTMD) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
biote has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
CytomX Therapeutics received 358 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 65.38% of users gave CytomX Therapeutics an outperform vote.
biote presently has a consensus price target of $10.50, indicating a potential upside of 133.85%. CytomX Therapeutics has a consensus price target of $5.77, indicating a potential upside of 640.06%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than biote.
biote has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
CytomX Therapeutics has a net margin of 10.96% compared to biote's net margin of 5.20%. biote's return on equity of -32.41% beat CytomX Therapeutics' return on equity.
21.7% of biote shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 13.9% of biote shares are held by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, biote and biote both had 1 articles in the media. biote's average media sentiment score of 1.93 beat CytomX Therapeutics' score of 1.11 indicating that biote is being referred to more favorably in the media.
Summary
biote beats CytomX Therapeutics on 12 of the 17 factors compared between the two stocks.
Get CytomX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytomX Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CTMX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CTMX Stock Alerts